{"id":35468,"date":"2026-06-19T16:06:12","date_gmt":"2026-06-19T10:36:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35468"},"modified":"2026-06-19T16:06:14","modified_gmt":"2026-06-19T10:36:14","slug":"evolution-of-biliary-tract-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment","title":{"rendered":"Navigating the Future of Biliary Tract Cancer Treatment: Precision Oncology and Emerging Therapeutic Strategies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a354ccd2a417\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a354ccd2a417\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#BTC_Treatment_Enters_the_Biomarker_Era_Beyond_Systemic_Therapies\" >BTC Treatment Enters the Biomarker Era: Beyond Systemic Therapies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Systemic_Therapy_Backbone_in_Advanced_Disease\" >Systemic Therapy Backbone in Advanced Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#How_Targeted_Therapies_are_Reshaping_the_BTC_Treatment\" >How Targeted Therapies are Reshaping the BTC Treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Tumor-agnostic_Targeting_Expands_Therapeutic_Opportunities\" >Tumor-agnostic Targeting Expands Therapeutic Opportunities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Current_Unmet_Needs\" >Current Unmet Needs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Advancing_the_Frontier_Momentum_in_BTC_Drug_Development\" >Advancing the Frontier: Momentum in BTC Drug Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Persistent_Need_for_Effective_Post-progression_Therapies\" >Persistent Need for Effective Post-progression Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Next-generation_Frontline_Combination_Strategies\" >Next-generation Frontline Combination Strategies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Immune_Modulation_Approaches\" >Immune Modulation Approaches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Novel_Therapeutic_Modalities_and_Platform_Innovation\" >Novel Therapeutic Modalities and Platform Innovation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Unlocking_the_Potential_of_Untapped_Early-stage_BTC_Market_Expansion\" >Unlocking the Potential of Untapped Early-stage BTC Market Expansion<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>The BTC treatment landscape is shifting from chemotherapy to precision oncology. While gemcitabine-based chemotherapy remains the backbone of first-line and advanced disease treatment, the field has increasingly moved toward biomarker-driven therapy and chemoimmunotherapy.<\/em><\/li>\n\n\n\n<li><em>Approved targeted therapies are now available for selected biomarker-defined patients. Key examples include FGFR2 inhibitors such as pemigatinib and futibatinib, IDH1 inhibitor ivosidenib, HER2-directed therapies such as trastuzumab deruxtecan and zanidatamab, and tumor-agnostic agents like larotrectinib, entrectinib, dabrafenib + trametinib, and selpercatinib.<\/em><\/li>\n\n\n\n<li><em>HER2 and FGFR2 are especially important emerging targets.<\/em><\/li>\n\n\n\n<li><em>The pipeline is expanding quickly. Emerging BTC research includes next-generation combinations, bispecific antibodies, immune-modulating approaches, and novel targets such as KRAS G12C, HER3, B7-H3, B7-H4, CLDN1, FGFR2b, CD47\/SIRP\u03b1, and TA-MUC1, signaling continued momentum in precision oncology.<\/em><\/li>\n<\/ul>\n\n\n\n<p>BTCs<strong> <\/strong>are a group of aggressive malignancies arising from the biliary epithelium, including <strong>ICC<\/strong>, <strong>ECC<\/strong>, <strong>GBC<\/strong>, and <strong>ampullary of vater cancer (AVC)<\/strong>. These tumors are often diagnosed at advanced stages due to nonspecific symptoms and a lack of screening strategies, resulting in poor prognosis and limited survival.&nbsp;<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Types of BTC<\/strong><\/td><td><strong>5-year Survival Rate of BTC<\/strong><\/td><td><strong>Patient Burden Trends of BTC<\/strong><\/td><\/tr><tr><td><strong>ICC<\/strong><\/td><td><sup>~<\/sup>9\u201310%<\/td><td>In Western countries, ICC incidence is often higher than ECC<\/td><\/tr><tr><td><strong>ECC<\/strong><\/td><td><sup>~<\/sup>10\u201315%<\/td><td>In East Asian countries like Japan, the proportion of ECC and gallbladder cancer cases is higher<\/td><\/tr><tr><td><strong>GBC<\/strong><\/td><td><sup>~<\/sup>20\u201325%<\/td><td>GBC incidence in the United States has generally been declining over the past two decades<\/td><\/tr><tr><td><strong>AVC<\/strong><\/td><td>~45\u201350%<\/td><td>Overall incidence of BTC in the UK is increasing across all subtypes, with the rise being gradual for AVC compared with more pronounced increases in iCCAs, eCCAs, and GBCs.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Over the past decade, the treatment paradigm has evolved significantly from reliance on surgery and cytotoxic chemotherapy toward biomarker-driven precision medicine supported by immunotherapy and targeted therapy innovations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-btc-treatment-enters-the-biomarker-era-beyond-systemic-therapies\"><span class=\"ez-toc-section\" id=\"BTC_Treatment_Enters_the_Biomarker_Era_Beyond_Systemic_Therapies\"><\/span><strong>BTC Treatment Enters the Biomarker Era: Beyond Systemic Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight estimates, there were approximately <strong>65,000<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-epidemiology-forecast\">incident cases of BTC<\/a> across the seven major markets, with <strong>nearly 30% <\/strong>of cases occurring in the United States. Japan has a high incidence rate of BTC when compared to Western countries. The BTC patient population is expected to grow over the forecast period, driven by increasing incidence and improved diagnosis rates. Among diagnosed patients, <strong>approximately 60\u201370% <\/strong>eventually progress from early-stage disease to advanced or metastatic BTC, highlighting the substantial burden of disease progression and the need for effective treatment options.&nbsp;<\/p>\n\n\n\n<p>Currently, the relapsed\/refractory BTC treatment landscape is largely dominated by therapies, including <strong>cytotoxic<\/strong> <strong>chemotherapy<\/strong> regimens such as <strong>FLOFOX<\/strong>, <strong>FOLFIRI<\/strong>, and liposomal irinotecan plus fluorouracil\/leucovorin. In recent years, the treatment paradigm has shifted toward biomarker-driven precision medicine, with several targeted therapies receiving regulatory approvals for molecularly defined patient subsets.<\/p>\n\n\n\n<p>These include <strong>pemigatinib <\/strong>(PEMAZYRE) by Incyte and <strong>futibatinib <\/strong>(LYTGOBI) by Taiho Oncology for patients with FGFR2 fusion-positive cholangiocarcinoma, <strong>ivosidenib <\/strong>(TIBSOVO) by Servier Pharmaceuticals for IDH1-mutated cholangiocarcinoma, <strong>larotrectinib <\/strong>(VITRAKVI) by Bayer\/Loxo Oncology and <strong>entrectinib <\/strong>(ROZLYTREK) by Roche\/Genentech for NTRK fusion-positive tumors, <strong>dabrafenib <\/strong>(TAFINLAR) <strong>plus trametinib <\/strong>(MEKINIST) by Novartis for BRAF V600E-mutated tumors, and <strong>selpercatinib <\/strong>(RETEVMO) by Eli Lilly for RET fusion-positive solid tumors, including cholangiocarcinoma.<\/p>\n\n\n\n<p>Development in the first-line BTC setting remains relatively limited compared with the relapsed\/refractory landscape, with treatment largely centered on chemotherapy-based regimens. Standard <a href=\"https:\/\/www.delveinsight.com\/blog\/biliary-tract-cancer-treatment-landscape\">first-line BTC treatment options<\/a> include <strong>gemcitabine plus cisplatin <\/strong>(GemCis), along with other recommended regimens such as <strong>gemcitabine plus nab-paclitaxel<\/strong>, <strong>cisplatin plus gemcitabine plus nab-paclitaxel<\/strong>, <strong>capecitabine plus oxaliplatin <\/strong>(CAPEOX), <strong>5-fluorouracil plus oxaliplatin <\/strong>(FOLFOX), and monotherapies including <strong>gemcitabine, capecitabine, or 5-fluorouracil<\/strong> for patients unsuitable for combination treatment. Recent advances have been driven primarily by the incorporation of immunotherapy into chemotherapy backbones.&nbsp;<\/p>\n\n\n\n<p>The neoadjuvant\/adjuvant BTC treatment market remains largely untapped, with limited approved therapies and significant unmet need. Current management is primarily based on perioperative chemotherapy and adjuvant treatment following surgical resection. <strong>Capecitabine <\/strong>(CAPE) is the preferred adjuvant regimen, while other recommended options include <strong>5-fluorouracil plus oxaliplatin <\/strong>(5-FU\/OX), <strong>capecitabine plus oxaliplatin <\/strong>(CAPEOX), <strong>gemcitabine combined with capecitabine<\/strong>,<strong> cisplatin<\/strong>,<strong> oxaliplatin<\/strong>,<strong> <\/strong>or<strong> nab-paclitaxel<\/strong>, as well as monotherapy with <strong>5-fluorouracil<\/strong>,<strong> capecitabine<\/strong>,<strong> <\/strong>or<strong> gemcitabine<\/strong>. Despite these chemotherapy-based approaches, no targeted therapies or immunotherapies have been widely established in the perioperative setting, highlighting a substantial opportunity for future therapeutic development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-systemic-therapy-backbone-in-advanced-disease\"><span class=\"ez-toc-section\" id=\"Systemic_Therapy_Backbone_in_Advanced_Disease\"><\/span><strong>Systemic Therapy Backbone in Advanced Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>For patients with unresectable locally advanced or metastatic disease, systemic therapy forms the cornerstone of treatment. Chemotherapy regimens based on gemcitabine combinations remain foundational first-line therapy across global clinical practice. The integration of immunotherapy has significantly changed frontline management, with immune checkpoint inhibitors now incorporated into treatment algorithms. <strong>Durvalumab <\/strong>(IMFINZI) represents a major advancement as an approved PD-1 inhibitor used in combination with chemotherapy in the first-line setting, demonstrating meaningful survival benefit. Similarly, <strong>pembrolizumab <\/strong>(KEYTRUDA)<strong> <\/strong>has expanded treatment options, particularly for biomarker-selected populations, reinforcing the growing role of immunotherapy in BTC management.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-targeted-therapies-are-reshaping-the-btc-treatment\"><span class=\"ez-toc-section\" id=\"How_Targeted_Therapies_are_Reshaping_the_BTC_Treatment\"><\/span><strong>How Targeted Therapies are Reshaping the BTC Treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In BTC, drug development is increasingly focused on biomarker-defined patient populations, with the greatest activity concentrated in FGFR2 fusions\/rearrangements and IDH1 mutations, particularly in intrahepatic cholangiocarcinoma. Companies such as Incyte, Taiho Oncology, and Servier have played a significant role in validating these targets, making them among the most established biomarker segments in BTC. Beyond these, substantial research activity is focused on HER2 amplification\/overexpression, with companies including <strong>AstraZeneca and Boehringer Ingelheim<\/strong> actively exploring <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-market-forecast\">HER2-targeted strategies<\/a>. Additional areas of interest include BRAF V600E mutations, NTRK fusions, RET fusions, and KRAS mutations, although these represent relatively smaller patient populations. Immunotherapy development is also focused on biomarkers such as PD-L1 expression, MSI-H\/dMMR, and tumor mutational burden (TMB-high) to better identify patients likely to benefit from checkpoint inhibition. More recently, companies have expanded their research efforts toward emerging targets such as CLDN18.2, EGFR, and components of the tumor microenvironment.<\/p>\n\n\n\n<p>FGFR-targeted therapies currently represent one of the most commercially attractive and clinically validated biomarker segments in BTC. Targeted therapies addressing BTC include<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pemigatinib <\/strong>(PEMAZYRE) and <strong>Futibatinib <\/strong>(LYTGOBI),<strong> <\/strong>both agents, have demonstrated clinical efficacy in patients with <strong>FGFR2 fusion-positive cholangiocarcinoma<\/strong>.<\/li>\n\n\n\n<li><strong>Zanidatamab <\/strong>(ZIIHERA) and<strong> Trastuzumab deruxtecan <\/strong>(ENHERTU)<strong> <\/strong>both have favorable clinical efficacy in HER-2 positive BTC, reinforcing HER2 as a promising therapeutic target and supporting continued development for HER2-directed treatment.<\/li>\n\n\n\n<li><strong>Ivosidenib <\/strong>(TIBSOVO)<strong> <\/strong>is approved for patients with <strong>IDH1-mutated<\/strong> BTC following prior systemic therapy. Only one IDH therapy.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"7\"><strong>HER2 Targeted Approved Therapies<\/strong><\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td><strong>Company Name<\/strong><\/td><td><strong>Approval<\/strong><strong>Year (the US)<\/strong><\/td><td><strong>Patient Segment<\/strong><\/td><td><strong>Pivotal Trial<\/strong><\/td><td><strong>Efficacy Insights<\/strong><\/td><td><strong>Safety Insights<\/strong><\/td><\/tr><tr><td><strong>Zanidatamab (ZIIHERA)<\/strong><\/td><td>Jazz Pharmaceuticals<\/td><td>2024<\/td><td>Metastatic HER2-positive (IHC 3+) BTC<\/td><td>HERIZON-BTC-01 (NCT04466891)<\/td><td><strong>ORR:<\/strong> 52%<strong>CR:<\/strong> 3.2%<strong>PR:<\/strong> 48%<\/td><td><strong>SAE:<\/strong> 53%Discontinuation: 2.5%<strong>Dosage interruptions:<\/strong> 41%<strong>Dosage reductions:<\/strong> 4%<\/td><\/tr><tr><td><strong>Trastuzumab deruxtecan (ENHERTU)<\/strong><\/td><td>AstraZeneca and Daiichi Sankyo<\/td><td>2024<\/td><td>Metastatic HER2-positive (IHC3+) solid tumors, including BTC<\/td><td>DESTINY-PanTumor02 (NCT04482309), DESTINY-Lung01 (NCT03505710), and DESTINY-CRC02 (NCT04744831)<\/td><td><strong>ORR:<\/strong> 45.5%DoR (months): 2.1<\/td><td><strong>SAE:<\/strong> 34%<strong>FAE:<\/strong> 6.3%<strong>Discontinuation:<\/strong> 15%<strong>Dose interruptions:<\/strong> 48%<strong>Dose reductions:<\/strong> 27%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"7\"><strong>FGFR Targeted Approved Therapies<\/strong><\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td><strong>Company Name<\/strong><\/td><td><strong>Approval<\/strong><strong>Year (Japan)<\/strong><\/td><td><strong>Patient Segment<\/strong><\/td><td><strong>Pivotal Trial<\/strong><\/td><td><strong>Efficacy Insights<\/strong><\/td><td><strong>Safety Insights<\/strong><\/td><\/tr><tr><td><strong>Tasurgratinib (TASFYGO)<\/strong><\/td><td>Eisai<\/td><td>2024<\/td><td>Unresectable BTC with FGFR2 gene fusions<\/td><td>Study 201 (NCT04238715)<\/td><td><strong>ORR<\/strong>: 30.2%<strong>PR<\/strong>: 30%<strong>SD<\/strong>: 49%<strong>DCR<\/strong>: 79%<strong>Clinical<\/strong> <strong>benefit<\/strong> <strong>rate<\/strong>: 51%<\/td><td><strong>\u22651 TRAE<\/strong>: 97%<strong>\u22651 Grade \u2265 3 TRAE<\/strong>: 29%<strong>Dose reduction<\/strong>: 54%<strong>Treatment interruption<\/strong>: 29%<strong>FAE<\/strong>: 6%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tumor-agnostic-targeting-expands-therapeutic-opportunities\"><span class=\"ez-toc-section\" id=\"Tumor-agnostic_Targeting_Expands_Therapeutic_Opportunities\"><\/span><strong>Tumor-agnostic Targeting Expands Therapeutic Opportunities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Tumor-agnostic targeted therapies have expanded treatment options for biomarker-selected patients with BTC. Collectively, these tumor-agnostic approvals emphasize the growing importance of comprehensive genomic profiling and personalized treatment selection in modern <a href=\"https:\/\/www.delveinsight.com\/blog\/biliary-tract-cancer-treatment-landscape\">BTC management<\/a>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Larotrectinib <\/strong>(VITRAKVI) and <strong>entrectinib <\/strong>(ROZLYTREK) are approved for tumors harboring <strong>NTRK gene fusions<\/strong>, irrespective of tumor origin, including BTC.\u00a0<\/li>\n\n\n\n<li><strong>Dabrafenib + trametinib <\/strong>(TAFINLAR + MEKINIST) provides an approved targeted treatment option for patients with <strong>BRAF V600E-mutated<\/strong> disease.\u00a0<\/li>\n\n\n\n<li><strong>Selpercatinib <\/strong>(RETEVMO) is an approved <strong>RET inhibitor<\/strong> indicated for patients with <strong>RET fusion-positive<\/strong> biliary tract cancers.\u00a0<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"4\"><strong>Genomic Alterations and Corresponding Targeted Therapeutic Strategies for BTCs<\/strong><\/td><\/tr><tr><td><strong>Molecular Alteration<\/strong><\/td><td><strong>Actionable Target<\/strong><\/td><td><strong>Available Drugs<\/strong><\/td><td><strong>Company Name<\/strong><\/td><\/tr><tr><td><strong>IDH1 mutation<\/strong><\/td><td>IDH inhibitors<\/td><td>Ivosidenib (TIBSOVO)<\/td><td>Agios Pharmaceuticals\/Servier Pharmaceuticals<\/td><\/tr><tr><td><strong>RET gene fusion<\/strong><\/td><td>Kinase inhibitors<\/td><td>Selpercatinib (RETEVMO)<\/td><td>Eli Lilly<\/td><\/tr><tr><td rowspan=\"2\"><strong>FGFR2<\/strong><\/td><td rowspan=\"2\">FGFR inhibitors<\/td><td>Futibatinib (LYTGOBI)<\/td><td>Taiho<\/td><\/tr><tr><td>Pemigatinib (PEMAZYRE)<\/td><td>Incyte<\/td><\/tr><tr><td rowspan=\"2\"><strong>TMB-H<\/strong><\/td><td rowspan=\"2\">ICIs<\/td><td>Pembrolizumab (KEYTRUDA)<\/td><td>Merck<\/td><\/tr><tr><td>Durvalumab (IMFINZI)<\/td><td>AstraZeneca<\/td><\/tr><tr><td><strong>BRAF V600E mutation<\/strong><\/td><td>BRAF inhibitors<\/td><td>Dabrafenib (TAFINLAR) + Trametinib (MEKINIST)<\/td><td>Novartis<\/td><\/tr><tr><td rowspan=\"2\"><strong>MSI-H\/dMMR<\/strong><\/td><td rowspan=\"2\">Immune checkpoint inhibitors<\/td><td>Pembrolizumab (KEYTRUDA)<\/td><td>Merck<\/td><\/tr><tr><td>Durvalumab (IMFINZI)<\/td><td>AstraZeneca<\/td><\/tr><tr><td rowspan=\"2\"><strong>NTRK gene fusion<\/strong><\/td><td rowspan=\"2\">NTRK inhibitors<\/td><td>Entrectinib (ROZLYTREK)<\/td><td>Roche\/Genentech<\/td><\/tr><tr><td>Larotrectinib (VITRAKVI)<\/td><td>Bayer\/Loxo Oncology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-current-unmet-needs\"><span class=\"ez-toc-section\" id=\"Current_Unmet_Needs\"><\/span><strong>Current Unmet Needs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A significant unmet need remains in BTC, as many biomarker-defined patient populations lack approved targeted therapies beyond established segments such as HER2, FGFR2, and IDH1. Despite advances in biomarker-driven therapy for BTC, several genomic alterations remain largely untapped or lack approved targeted treatment options. Common alterations such as CDKN2A\/B, TP53, ARID1A, KRAS, SMAD4, and PBRM1, along with less frequent but actionable biomarkers including BRAF, NTRK1, RET fusions, MSI-H\/dMMR, and TMB-H, represent significant opportunities for therapeutic development. Expanding effective targeted and biomarker-guided treatment strategies for these patient subsets remains a key unmet need in BTC.<\/p>\n\n\n\n<p>Furthermore, apart from <a href=\"https:\/\/www.delveinsight.com\/report-store\/immune-checkpoint-inhibitors-market\">immune checkpoint inhibitor (ICI)-based combinations<\/a>, there are limited approved biomarker-directed therapies in the first-line setting, highlighting a significant need for novel targeted treatments that can improve outcomes for these patient populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-advancing-the-frontier-momentum-in-btc-drug-development\"><span class=\"ez-toc-section\" id=\"Advancing_the_Frontier_Momentum_in_BTC_Drug_Development\"><\/span><strong>Advancing the Frontier: Momentum in BTC Drug Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-pipeline-insight\">BTC pipeline<\/a> is expanding across a diverse range of emerging biomarkers and targets, including <strong>LAT1<\/strong>, <strong>DLL4\/VEGF-A<\/strong>, <strong>GRP78<\/strong>, <strong>CK2<\/strong>, <strong>HER3<\/strong>, <strong>KRAS<\/strong> <strong>G12C<\/strong>, <strong>CD47\/SIRP\u03b1<\/strong>, <strong>CLDN1<\/strong>, <strong>FGFR2b<\/strong>, <strong>B7-H3<\/strong>, <strong>B7-H4<\/strong>, and <strong>TA-MUC1<\/strong>. This growing biomarker diversity highlights the increasing role of precision oncology and immuno-oncology in BTC development.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"606\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-1024x606.webp\" alt=\"Emerging-Biliary-Tract-Cancer-Drugs-in-Development\" class=\"wp-image-34335\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-1024x606.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-300x178.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-150x89.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-768x455.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development-1536x909.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Emerging-Biliary-Tract-Cancer-Drugs-in-Development.webp 1824w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-persistent-need-for-effective-post-progression-therapies\"><span class=\"ez-toc-section\" id=\"Persistent_Need_for_Effective_Post-progression_Therapies\"><\/span><strong>Persistent Need for Effective Post-progression Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Tinengotinib<\/strong> (TransThera Sciences) and <strong>Nanvuranlat<\/strong> (J-Pharma\/OHARA Pharmaceutical) are in <strong>Phase III<\/strong> development for previously treated advanced BTC patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-generation-frontline-combination-strategies\"><span class=\"ez-toc-section\" id=\"Next-generation_Frontline_Combination_Strategies\"><\/span><strong>Next-generation Frontline Combination Strategies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The frontline BTC landscape is evolving with novel antibody-based therapies, including <strong>Zanidatamab<\/strong> <strong>(ZIIHERA)<\/strong> plus chemotherapy, <strong>trastuzumab<\/strong> <strong>deruxtecan<\/strong> (ENHERTU) plus <strong>rilvegostomig<\/strong>, and <strong>rilvegostomig<\/strong> with chemotherapy, all being evaluated in Phase III studies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-immune-modulation-approaches\"><span class=\"ez-toc-section\" id=\"Immune_Modulation_Approaches\"><\/span><strong>Immune Modulation Approaches<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Additional innovative therapies in BTC include <strong>tovecimig<\/strong>, a <strong>DLL4\/VEGF-A bispecific antibody<\/strong> being evaluated in combination regimens across first- and later-line settings, and <strong>silmitasertib<\/strong> <strong>(CX-4945),<\/strong> a Casein Kinase 2 (CK2) inhibitor in <strong>Phase II<\/strong> development for <strong>cholangiocarcinoma<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novel-therapeutic-modalities-and-platform-innovation\"><span class=\"ez-toc-section\" id=\"Novel_Therapeutic_Modalities_and_Platform_Innovation\"><\/span><strong>Novel Therapeutic Modalities and Platform Innovation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Novel <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-pipeline-insight\">BTC therapies<\/a> under development include <strong>VG161<\/strong>, an oncolytic virus therapy, <strong>BOLD-100<\/strong>, a GRP78 inhibitor combined with <strong>FOLFOX<\/strong>, and <strong>tucatinib (TUKYSA)<\/strong>, an oral HER2-targeted tyrosine kinase inhibitor, all being evaluated in Phase II studies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-unlocking-the-potential-of-untapped-early-stage-btc-market-expansion\"><span class=\"ez-toc-section\" id=\"Unlocking_the_Potential_of_Untapped_Early-stage_BTC_Market_Expansion\"><\/span><strong>Unlocking the Potential of Untapped Early-stage BTC Market Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In early-stage BTC, surgical resection remains the only potentially curative treatment and the standard approach. Among emerging therapies, <strong>rilvegostomig<\/strong>, a <strong>PD-1\/TIGIT bispecific antibody<\/strong> developed by <strong>AstraZeneca<\/strong> and <strong>Compugen<\/strong>, is being evaluated in the Phase III ARTEMIDE-Biliary02 trial. If successful, it could be <strong>launched<\/strong> around <strong>2030<\/strong>, providing a novel immunotherapy option for BTC.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/biliary-tract-cancer-treatment-landscape\">BTC development landscape<\/a> is witnessing growing interest from a diverse group of biotechnology and pharmaceutical companies, reflecting the increasing recognition of the disease\u2019s unmet medical need and commercial potential.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The BTC treatment landscape has evolved from a predominantly chemotherapy-based approach to one increasingly driven by chemoimmunotherapy and biomarker-targeted therapies, with approved options for FGFR2, IDH1, HER2, BRAF, NTRK, and RET-altered tumors. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\">BTC clinical trial pipeline<\/a> continues to expand with novel immunotherapies, bispecific antibodies, and next-generation targeted agents. However, significant unmet needs remain, particularly for patients without actionable mutations and in the neoadjuvant\/adjuvant setting, where treatment options are limited, and recurrence rates remain high. Looking ahead, untapped biomarker segments such as <strong>KRAS G12C, HER3, B7-H3, B7-H4, CLDN1, FGFR2b, c-MET, and CD47\/SIRP\u03b1 <\/strong>present promising opportunities to broaden precision medicine approaches and drive the next wave of innovation in BTC.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-1024x194.webp\" alt=\"Biliary Tract Cancer Market Outlook\" class=\"wp-image-34334\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/Biliary-Tract-Cancer-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary BTCs are a group of aggressive malignancies arising from the biliary epithelium, including ICC, ECC, GBC, and ampullary of vater cancer (AVC). These tumors are often diagnosed at advanced stages due to nonspecific symptoms and a lack of screening strategies, resulting in poor prognosis and limited survival.&nbsp; Types of BTC 5-year Survival Rate of [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16752,22847,16753,16751,21478,16754],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-35468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biliary-tract-cancer","tag-biliary-tract-cancer-drugs","tag-biliary-tract-cancer-incidence","tag-biliary-tract-cancer-market","tag-biliary-tract-cancer-treatment","tag-btc","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Evolution of Biliary Tract Cancer Treatment<\/title>\n<meta name=\"description\" content=\"The biliary tract cancer (BTC) treatment market landscape is shifting from chemotherapy to precision oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Evolution of Biliary Tract Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"The biliary tract cancer (BTC) treatment market landscape is shifting from chemotherapy to precision oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-19T10:36:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-19T10:36:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Evolution of Biliary Tract Cancer Treatment","description":"The biliary tract cancer (BTC) treatment market landscape is shifting from chemotherapy to precision oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment","og_locale":"en_US","og_type":"article","og_title":"The Evolution of Biliary Tract Cancer Treatment","og_description":"The biliary tract cancer (BTC) treatment market landscape is shifting from chemotherapy to precision oncology.","og_url":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-06-19T10:36:12+00:00","article_modified_time":"2026-06-19T10:36:14+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment","url":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment","name":"The Evolution of Biliary Tract Cancer Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment.webp","datePublished":"2026-06-19T10:36:12+00:00","dateModified":"2026-06-19T10:36:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The biliary tract cancer (BTC) treatment market landscape is shifting from chemotherapy to precision oncology.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/evolution-of-biliary-tract-cancer-treatment#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment.webp","width":466,"height":284,"caption":"evolution-of-biliary-tract-cancer-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/evolution-of-biliary-tract-cancer-treatment-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biliary tract cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biliary Tract Cancer Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biliary tract cancer incidence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biliary tract cancer market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">biliary tract cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BTC<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biliary tract cancer<\/span>","<span class=\"advgb-post-tax-term\">Biliary Tract Cancer Drugs<\/span>","<span class=\"advgb-post-tax-term\">Biliary tract cancer incidence<\/span>","<span class=\"advgb-post-tax-term\">Biliary tract cancer market<\/span>","<span class=\"advgb-post-tax-term\">biliary tract cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">BTC<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 hours ago","modified":"Updated 2 hours ago"},"absolute_dates":{"created":"Posted on Jun 19, 2026","modified":"Updated on Jun 19, 2026"},"absolute_dates_time":{"created":"Posted on Jun 19, 2026 4:06 pm","modified":"Updated on Jun 19, 2026 4:06 pm"},"featured_img_caption":"evolution-of-biliary-tract-cancer-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35468"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35468\/revisions"}],"predecessor-version":[{"id":35472,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35468\/revisions\/35472"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35470"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35468"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35468"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}